Current Issue


Physician, practice characteristics may affect diabetes care quality

A systematic review and meta-analysis found that physicians who were female, treated diabetes more often, and used electronic health records were associated with higher-quality care in adults with diabetes.

HbA1c testing in barbershops identified black men with undiagnosed diabetes

About one-third of men approached in barbershops owned by black individuals were willing to be screened for diabetes, and 9% of them had undiagnosed diabetes while 28% had prediabetes.

SGLT-2 inhibitors reduced risk of cardiovascular disease, death, review finds

The authors of a systematic review and meta-analysis recommended reconsideration of guidelines on sodium-glucose cotransporter-2 (SGLT-2) inhibitors to increase use among patients at risk of cardiovascular disease.

MKSAP quiz: Weight loss plan

This month's quiz asks readers to evaluate a 43-year-old patient with obesity and type 2 diabetes who has not had success with recent weight loss efforts.

Spotlight on the effects of exercise in diabetes

Studies published in the past month looked at how exercise and indicators of fitness among patients with diabetes are associated with mortality risk, vascular health, and medication use.

In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding

Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.

SGLT-2 inhibitors associated with lower risk of gout vs. GLP-1 receptor agonists

In a large, propensity-matched study, adult patients with type 2 diabetes who were newly prescribed a sodium-glucose cotransporter-2 (SGLT-2) inhibitor had a lower rate of incident gout than those newly prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist.

Metformin testing finds negligible levels of nitrosamine impurity

Levels of N-nitrosodimethylamine found in metformin products ranged from not detectable to low, and there are no U.S. recalls at this time.